MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1007/s10549-026-08012-5

Медицинская библиотека · Breast cancer research and treatment · 2026

EVERolimus effectiveness after proGREssion on ENdocrine therapy plus CDK4/6 inhibitor for ER-positive/HER2-negative advanced breast cancer: EVERGREEN study.

Martins-Branco Diogo, Lobo-Martins Soraia, Aftimos Philippe, Pereira Bernardo, Vasconcelos de Matos Leonor, Fernandes Leonor, Campôa Elsa, Nader-Marta Guilherme, Moreau Michel, Taylor Donatienne, Duhoux Francois P, Simões Pedro, Garcia Ana Rita, Patel Vanessa, Confente Caterina, Alpuim Costa Diogo, Pereira José, Santos Catarina, Paesmans Marianne, Sarmento Frederico, Gantes Padrão Teresa, Simão Diana, Bandarra Daniel, Sousa Berta, Brito Margarida, Gombos Andrea, Ameye Lieveke, de Azambuja Evandro

Сравнительное исследованиеСтатьяМногоцентровое исследованиеПеревод в очереди

Аннотация

PURPOSE: There is limited evidence supporting the addition of everolimus to endocrine therapy in women with ER-positive/HER2-negative advanced breast cancer disease progression on CDK4/6 inhibitors. We aimed to assess the effectiveness and safety of everolimus in this setting.

METHODS

EVERGREEN is a multicentre, international, retrospective quasi-experimental study of women with ER-positive/HER2-negative advanced breast cancer who started an immediate next line of endocrine therapy after progression on CDK4/6 inhibitors until 31/12/2022. We compared patients exposed to endocrine therapy plus everolimus in centres where this is the standard-of-care with those treated in centres where endocrine therapy alone is the standard-of-care. The primary endpoint was real-world progression-free survival (rwPFS). Secondary endpoints were time to everolimus failure, time to chemotherapy, and overall survival.

RESULTS

We included 207 women (everolimus n = 150, endocrine therapy alone n = 57), with a median follow-up of 31.8 months. Baseline characteristics were well balanced, except for a higher number of prior lines of therapy in the everolimus cohort. Median rwPFS was 5.0 for patients exposed to everolimus vs 4.3 months for endocrine therapy alone (adjusted hazard ratio 0.68, 95% confidence interval 0.47-0.99). Time to everolimus failure was 4.2 months. There were no statistically significant differences in time to chemotherapy or overall survival. The safety profile was consistent with previous reports.

CONCLUSION

The addition of everolimus to standard endocrine therapy resulted in a modest clinical benefit for patients with ER-positive/HER2-negative advanced breast cancer candidates for endocrine therapy after CDK4/6 inhibitors. This limited benefit and the toxicity profile warrants careful selection of patients with favourable risk-benefit profile.

Для цитирования: Martins-Branco Diogo, Lobo-Martins Soraia, Aftimos Philippe, Pereira Bernardo, Vasconcelos de Matos Leonor, Fernandes Leonor, Campôa Elsa, Nader-Marta Guilherme, Moreau Michel, Taylor Donatienne, Duhoux Francois P, Simões Pedro, Garcia Ana Rita, Patel Vanessa, Confente Caterina, Alpuim Costa Diogo, Pereira José, Santos Catarina, Paesmans Marianne, Sarmento Frederico, Gantes Padrão Teresa, Simão Diana, Bandarra Daniel, Sousa Berta, Brito Margarida, Gombos Andrea, Ameye Lieveke, de Azambuja Evandro. EVERolimus effectiveness after proGREssion on ENdocrine therapy plus CDK4/6 inhibitor for ER-positive/HER2-negative advanced breast cancer: EVERGREEN study.. Breast cancer research and treatment. 2026. DOI: 10.1007/s10549-026-08012-5.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.